Your Health, We Care
Entretinib, as a targeted drug targeting NTRK gene fusion and other specific gene mutations, continues to make progress in international research.
Entrectinib can cross the blood-brain barrier and has therapeutic effects on primary and metastatic brain diseases, which has been validated in studies targeting ROS1 fusion positive non-small cell lung cancer (NSCLC) patients.
